SomnoMed Limited reported unaudited earnings results for the full year of 2018. For the full year, the company reported group revenues of $63.6 million, representing growth of 29% over prior year. SomnoMed core revenues were $52.4 million, up 10% from 2017 and Renew Sleep Solutions revenues were $11.2 million, and up from $1.6 million in 2017. The Group EBITDA loss for the year is $6.5 million. SomnoMed's core division contributed a positive $3.9m to this result, with RSS's annual loss at $10.4 million. In summary, the SomnoMed Group posted strong revenue growth for FY18 but disappointing group EBITDA results due to RSS. Net operating cash flow for the year was a negative $9.5 million, after the investment made in RSS for the year at $13 million, indicating a positive cash year for SomnoMed's core business of $3.5 million.

For the fiscal year 2019, the company expects SomnoMed core business revenue growth of 15% to $60 million. EBITDA between $5 million to $5.5 million. RSS business Revenue growth between 25%-35% to between $14 million to $15 million. EBITDA loss of between $5 million to $6 million, representing a conservative guidance given the current risk.